NasdaqCM:CORTPharmaceuticals
Corcept Therapeutics (CORT): Reassessing Valuation After Q3 Earnings Beat, Revenue Miss, and Planned CEO Share Sale
Corcept Therapeutics (CORT) just posted third quarter earnings that topped profit expectations even as revenue missed forecasts, and the update landed alongside a pre planned 40,000 share sale by CEO Joseph Belanoff.
See our latest analysis for Corcept Therapeutics.
The stock has been climbing steadily, with a 72.31% year to date share price return and a 302.74% three year total shareholder return suggesting momentum is still firmly building behind the story.
If Corcept’s run has you...